. Author manuscript; available in PMC: 2011 Jan 15.

Published in final edited form as: Clin Cancer Res. 2010 Jan 12;16(2):681–690. doi: 10.1158/1078-0432.CCR-09-1091

Table 2.

Biomarker analysis in taxane-neoadjuvant breast cancer biopsies

	Score	NR, n (% of score)	pCR, n (% of score)	OR (95% CI)
DEFA	0	8 (100%)	0 (0%)	3.4 (1.4–8.1), P = 0.007
	+1	17 (81.0%)	4 (19.1%)
	+2	13 (56.5%)	10 (43.5%)
	+3	2 (40.0%)	3 (60.0%)
Inflammation	0	4 (100%)	0 (0%)	2.3 (1.1–4.9), P = 0.031
	+1	22 (88.0%)	3 (12.0%)
	+2	13 (61.9%)	8 (38.1%)
	+3	7 (63.6%)	4 (36.4%)
MAP2^*		P50 (P25–P75)	P50 (P25–P75)	3.2 (1.1–9.3), P = 0.037
MAP2^*		33.3 (18.3–38.3)	35.0 (31.7–40.0)

Abbreviations: P50, median (P25, 25th percentile; P75, 75th percentile); OR, odds ratio; 95% CI, 95% confidence interval.

Weighted index of MAP2 expression (Materials and Methods).